Nataliia Maksymovych
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nataliia Maksymovych has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Olha Zaliska
SNE «Danylo Halytsky Lviv National Medical University», Lviv, Ukraine
10 shared publications - V. S. Huz
Львівський національний медичний університет імені Данила Галицького
3 shared publications O Brezden
2 shared publicationsO Zalis'Ka
2 shared publicationsO. Zalis’ka
2 shared publications- Orest Sichkoriz
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
2 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 4,p. 35-44
Marketing research of medicinal products used for the treatment of primary cicatricial alopecia
Primary cicatricial alopecias belong to a group of chronic inflammatory diseases of the hair follicles that lead to their irreversible destruction and the formation of scar tissue. The complexity of diagnosis, limited therapeutic options, and the lack of unified approaches to treatment necessitate an assessment of the current range of medicinal products available for the pharmacotherapy of this pathology. The aim of the study was to investigate the structure and range of medicinal products on the domestic pharmaceutical market that are used for the treatment of primary cicatricial alopecias. The materials of the study were data on medicinal products registered on the pharmaceutical market of Ukraine as of 01.01.2026. Due to the absence of unified treatment protocols for primary cicatricial alopecias, the selection of medicinal products for marketing analysis was carried out on the basis of an analysis of current international scientific publications, clinical recommendations of professional dermatological associations, and data on the use of medicinal products in real clinical practice. It was established that 118 trade names (TNs) of medicinal products that can be used for the treatment of primary cicatricial alopecias are registered on the pharmaceutical market of Ukraine. By manufacturer origin, imported medicinal products predominate – 91 TNs (79%), whereas the share of domestic medicinal products is 27 TNs (21%). Capsules and tablets account for a significant share of the range – 35 TNs. Among medicinal products for topical use, ointments and creams predominate – 50 TNs, whereas systemic glucocorticosteroids are represented exclusively by injectable dosage forms. By composition, monocomponent medicinal products predominate – 89 TNs (75%), including all medicinal products of isotretinoin, tacrolimus, pimecrolimus, colchicine, hydroxychloroquine, and antibiotics. Combined medicinal products account for 29 TNs (25%) and are represented predominantly by betamethasone preparations for topical use. The results of the study indicate a significant dependence of the studied market segment on imported medicinal products and a limited range of agents for the treatment of primary cicatricial alopecias. The obtained data may be used to substantiate the prospects for expanding the range and developing domestic production of medicinal products for the treatment of primary cicatricial alopecias.
- 28 August 2026
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 4,p. 35-44
Open AccessMarketing research of medicinal products used for the treatment of primary cicatricial alopecia
Primary cicatricial alopecias belong to a group of chronic inflammatory diseases of the hair follicles that lead to their irreversible destruction and the formation of scar tissue. The complexity of diagnosis, limited therapeutic options, and the lack of unified approaches to treatment necessitate an assessment of the current range of medicinal products available for the pharmacotherapy of this pathology. The aim of the study was to investigate the structure and range of medicinal products on the domestic pharmaceutical market that are used for the treatment of primary cicatricial alopecias. The materials of the study were data on medicinal products registered on the pharmaceutical market of Ukraine as of 01.01.2026. Due to the absence of unified treatment protocols for primary cicatricial alopecias, the selection of medicinal products for marketing analysis was carried out on the basis of an analysis of current international scientific publications, clinical recommendations of professional dermatological associations, and data on the use of medicinal products in real clinical practice. It was established that 118 trade names (TNs) of medicinal products that can be used for the treatment of primary cicatricial alopecias are registered on the pharmaceutical market of Ukraine. By manufacturer origin, imported medicinal products predominate – 91 TNs (79%), whereas the share of domestic medicinal products is 27 TNs (21%). Capsules and tablets account for a significant share of the range – 35 TNs. Among medicinal products for topical use, ointments and creams predominate – 50 TNs, whereas systemic glucocorticosteroids are represented exclusively by injectable dosage forms. By composition, monocomponent medicinal products predominate – 89 TNs (75%), including all medicinal products of isotretinoin, tacrolimus, pimecrolimus, colchicine, hydroxychloroquine, and antibiotics. Combined medicinal products account for 29 TNs (25%) and are represented predominantly by betamethasone preparations for topical use. The results of the study indicate a significant dependence of the studied market segment on imported medicinal products and a limited range of agents for the treatment of primary cicatricial alopecias. The obtained data may be used to substantiate the prospects for expanding the range and developing domestic production of medicinal products for the treatment of primary cicatricial alopecias.
- Open Access
- 17 February 2022
- Published by Ternopil State Medical University in Фармацевтичний часопис
- No. 4,p. 53-62
АНАЛІЗ ТЕНДЕНЦІЙ У ПРОГРАМІ РЕІМБУРСАЦІЇ «ДОСТУПНІ ЛІКИ» В УКРАЇНІ
Мета роботи. Провести аналіз упровадження урядової програми реімбурсації «Доступні ліки» для амбулаторного лікування основними лікарськими засобами пацієнтів із серцево-судинними захворюваннями, цукровим діабетом 2 типу та бронхіальною астмою за 2019–2020 роки. Матеріали і методи. Об’єктами дослідження були дані з НСЗУ за 2019–2020 роки, а також Постанови КМУ, Накази МОЗ України про затвердження Реєстру лікарських засобів, вартість яких підлягає відшкодуванню у програмі «Доступні ліки». У дослідженні було використано методи частотного, порівняльного, логічного та контент-аналізу. Результати й обговорення. Розроблено методику аналізу програми реімбурсації з урахуванням районування території України за 5 макрорегіонами та проведено аналіз таких показників, як: бюджетне фінансування програми; кількість виписаних та відпущених електронних рецептів з 01 квітня 2019 року; розподіл електронних рецептів у програмі за віком та статтю пацієнтів; структура аптек за формою власності та типом населеного пункту. Виявлено, що обсяг бюджетного фінансування програми «Доступні ліки» у 2020 році зріс у 3 рази порівняно з 2017 роком. Кількість аптек у 2020 році зросла в 1,84 раза порівняно зі стартом програми. Більшість залучених до програми аптек розташована в містах Західного та Центрального макрорегіону. Встановлено, що у 2020 році найвищі темпи приросту, за досліджуваними параметрами, зафіксовані у Південному та Західному макрорегіонах країни. Впродовж 2019–2020 років понад 50 % е-рецептів було виписано на такі міжнародні непатентовані назви (МНН): бісопролол, клопідогрель, еналаприл та амлодипін. Висновки. Проведений аналіз програми реімбурсації виявив збільшення кількості аптек у 1,84 раза порівняно зі стартом програми у 2017 році. Згідно з регіональним розподілом та аналізом показників, найвищі показники приросту встановлені у Південному макрорегіоні. За досліджуваний період більше 50 % з усіх е-рецептів для лікування АГ було виписано для таких лікарських засобів як: бісопролол, клопідогрель, еналаприл та амлодипін.
- 17 February 2022
- Published by Ternopil State Medical University in Фармацевтичний часопис
- No. 4,p. 53-62
Open AccessАНАЛІЗ ТЕНДЕНЦІЙ У ПРОГРАМІ РЕІМБУРСАЦІЇ «ДОСТУПНІ ЛІКИ» В УКРАЇНІ
Мета роботи. Провести аналіз упровадження урядової програми реімбурсації «Доступні ліки» для амбулаторного лікування основними лікарськими засобами пацієнтів із серцево-судинними захворюваннями, цукровим діабетом 2 типу та бронхіальною астмою за 2019–2020 роки. Матеріали і методи. Об’єктами дослідження були дані з НСЗУ за 2019–2020 роки, а також Постанови КМУ, Накази МОЗ України про затвердження Реєстру лікарських засобів, вартість яких підлягає відшкодуванню у програмі «Доступні ліки». У дослідженні було використано методи частотного, порівняльного, логічного та контент-аналізу. Результати й обговорення. Розроблено методику аналізу програми реімбурсації з урахуванням районування території України за 5 макрорегіонами та проведено аналіз таких показників, як: бюджетне фінансування програми; кількість виписаних та відпущених електронних рецептів з 01 квітня 2019 року; розподіл електронних рецептів у програмі за віком та статтю пацієнтів; структура аптек за формою власності та типом населеного пункту. Виявлено, що обсяг бюджетного фінансування програми «Доступні ліки» у 2020 році зріс у 3 рази порівняно з 2017 роком. Кількість аптек у 2020 році зросла в 1,84 раза порівняно зі стартом програми. Більшість залучених до програми аптек розташована в містах Західного та Центрального макрорегіону. Встановлено, що у 2020 році найвищі темпи приросту, за досліджуваними параметрами, зафіксовані у Південному та Західному макрорегіонах країни. Впродовж 2019–2020 років понад 50 % е-рецептів було виписано на такі міжнародні непатентовані назви (МНН): бісопролол, клопідогрель, еналаприл та амлодипін. Висновки. Проведений аналіз програми реімбурсації виявив збільшення кількості аптек у 1,84 раза порівняно зі стартом програми у 2017 році. Згідно з регіональним розподілом та аналізом показників, найвищі показники приросту встановлені у Південному макрорегіоні. За досліджуваний період більше 50 % з усіх е-рецептів для лікування АГ було виписано для таких лікарських засобів як: бісопролол, клопідогрель, еналаприл та амлодипін.
- Open Access
- 9 December 2020
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 6,p. 16-25
Study of the pharmacist role in ensuring of quarantine measures during the COVID-19 pandemic
The pharmacist as a member of the medical team is responsible for the life and health of the population in the context of the COVID-19 pandemic in accordance with the recommendations of WHO and FIP, 2020. According to the WHO, 82% of patients with COVID-19 are treated by a family doctors and receive pharmaceutical care at the nearest pharmacies, but this can lead to unwanted contact between infected and healthy people, as well as contact with a pharmacist when dispensing drugs, which can lead to COVID-19 infection. Compliance with quarantine measures in accordance with the Resolutions of the Cabinet of Ministers and Orders of the Ministry of Health of Ukraine in pharmacies is an important component of overall safety during a pandemic, and the role of pharmacists in preventing the COVID-19 pandemic is important. The aim of this study was to conduct an expert evaluation of the effectiveness of quarantine measures due to the orders of the Ministry of Health of Ukraine in pharmacies. The sample of 586 experts included pharmacists, heads of pharmacies in 6 regions of Ukraine: Lviv, Vinnytsia, Ivano-Frankivsk, Zakarpattia, Khmelnytsky, Chernivtsi. According to a specially developed questionnaire «Assessment of the effectiveness of quarantine measures in the pharmacy at COVID-19» pharmacists were interviewed during March-October 2020. Methods of face-to-face questionnaires, interviews with the help of information and communication technologies, methods of generalization and systematization are used. According to the results of the analysis of 586 questionnaires, the respondents were ranked according to the parameters: specialty, work experience, qualification category. It was found that in 97.5% of pharmacies quarantine measures were implemented in March, in 2.5% pharmacies were in April 2020. The results of the pharmacists' survey show that the most effective quarantine measures are: wearing a protective mask (99.0%), washing hands and using disinfectants (97.0%), maintaining a social distance between visitors and pharmacy staff, as well as visitors to each other 1.5 m (94.5%), washingof pharmacy surfaces and floors with disinfectant solutions (91.0%), ventilation of pharmacy rooms (89.5%). Systematization of these questionnaires showed that 100% of pharmacists consider it necessary and prospective the approval by Ministry of Health of Ukraine a separate «Protocol of the pharmacist for the release of medicines and medical devices for the treatment of uncomplicated forms of coronavirus infection COVID-19» to optimize pharmaceutical care. Pharmacist as member of the medical team during the COVID-19 pandemic should conduct educational work among the population to prevent the spread of the COVID-19 pandemic.
- 9 December 2020
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 6,p. 16-25
Open AccessStudy of the pharmacist role in ensuring of quarantine measures during the COVID-19 pandemic
The pharmacist as a member of the medical team is responsible for the life and health of the population in the context of the COVID-19 pandemic in accordance with the recommendations of WHO and FIP, 2020. According to the WHO, 82% of patients with COVID-19 are treated by a family doctors and receive pharmaceutical care at the nearest pharmacies, but this can lead to unwanted contact between infected and healthy people, as well as contact with a pharmacist when dispensing drugs, which can lead to COVID-19 infection. Compliance with quarantine measures in accordance with the Resolutions of the Cabinet of Ministers and Orders of the Ministry of Health of Ukraine in pharmacies is an important component of overall safety during a pandemic, and the role of pharmacists in preventing the COVID-19 pandemic is important. The aim of this study was to conduct an expert evaluation of the effectiveness of quarantine measures due to the orders of the Ministry of Health of Ukraine in pharmacies. The sample of 586 experts included pharmacists, heads of pharmacies in 6 regions of Ukraine: Lviv, Vinnytsia, Ivano-Frankivsk, Zakarpattia, Khmelnytsky, Chernivtsi. According to a specially developed questionnaire «Assessment of the effectiveness of quarantine measures in the pharmacy at COVID-19» pharmacists were interviewed during March-October 2020. Methods of face-to-face questionnaires, interviews with the help of information and communication technologies, methods of generalization and systematization are used. According to the results of the analysis of 586 questionnaires, the respondents were ranked according to the parameters: specialty, work experience, qualification category. It was found that in 97.5% of pharmacies quarantine measures were implemented in March, in 2.5% pharmacies were in April 2020. The results of the pharmacists' survey show that the most effective quarantine measures are: wearing a protective mask (99.0%), washing hands and using disinfectants (97.0%), maintaining a social distance between visitors and pharmacy staff, as well as visitors to each other 1.5 m (94.5%), washingof pharmacy surfaces and floors with disinfectant solutions (91.0%), ventilation of pharmacy rooms (89.5%). Systematization of these questionnaires showed that 100% of pharmacists consider it necessary and prospective the approval by Ministry of Health of Ukraine a separate «Protocol of the pharmacist for the release of medicines and medical devices for the treatment of uncomplicated forms of coronavirus infection COVID-19» to optimize pharmaceutical care. Pharmacist as member of the medical team during the COVID-19 pandemic should conduct educational work among the population to prevent the spread of the COVID-19 pandemic.
- Open Access
- 30 July 2020
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 4,p. 49-59
Assessment of availability of assisted reproductive technologies in Ukraine and the world
In Ukraine, in order to achieve the Sustainable Development Goals, the State Strategy for the Implementation of the State Policy for the Provision of the Population with Medicines for the Period until 2025 has been approved, which includes improving the availability of drugs to improve the quality of life. Assisted Reproductive Technologies (ART) are gaining widespread implementation and funding from the budget in the world. Goal – the aim of the work was to analyze the state and dynamics of ART cycles in Ukraine for 1999–2019 and to estimate the cost of ART in Ukraine and to develop a methodology for estimating the availability of ART and comparison with European countries. Materials – international and domestic publications on the assessment of the availability of drugs, the cost of ART. Research methods: system analysis, data synthesis and generalization of information, webometric analysis, statistical analysis of data on the number of ART cycles for 1999-2018, analysis of ART costs. It is determined that the indicator of the number of ART cycles per 1 million population increased 29.9 times for 1999–2018, which is due to the increase in the number of ART centers conducted ART cycles in relation to the decrease in the population of Ukraine. It was found that 85% of ART centers are concentrated in only 4 cities (Kyiv, Lviv, Odessa, Kharkiv), which reduces the accessibility of the population to ART cycles, especially in the conditions of quarantine and pandemic COVID-19. It was found that in 1999–2018 the number of ART centers increased 7.7 times, but only 10.8% of ART centers have state funding, which indicates the low availability of ART for budget funds. It was found that the structure of ART cycles changed significantly. The average costs for the most common ART cycles IVF and ICSI in Ukraine as of the end of 2019 have been determined. It has been shown that only 26% of ART centers provide information on the cost of ART cycles, and web pages need to be filled with information on the cost of ART cycles to ensure that patients are properly informed. It is shown that in Ukraine as of 2020 the costs of ART cycles are 24 425–30 516 UAH (917,25–1 010,57 Euro) depending on the type of cycle from the perspective of the payer. It is estimated that the availability of ART is 1.5–9.98 depending on the type of ART cycle, the cost of ART cycles is 6–10 times higher than the average family income, when in European countries the availability of ART is much lower 1,5–4.2, which showed higher availability of ART in European countries from payer prospect.
- 30 July 2020
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 4,p. 49-59
Open AccessAssessment of availability of assisted reproductive technologies in Ukraine and the world
In Ukraine, in order to achieve the Sustainable Development Goals, the State Strategy for the Implementation of the State Policy for the Provision of the Population with Medicines for the Period until 2025 has been approved, which includes improving the availability of drugs to improve the quality of life. Assisted Reproductive Technologies (ART) are gaining widespread implementation and funding from the budget in the world. Goal – the aim of the work was to analyze the state and dynamics of ART cycles in Ukraine for 1999–2019 and to estimate the cost of ART in Ukraine and to develop a methodology for estimating the availability of ART and comparison with European countries. Materials – international and domestic publications on the assessment of the availability of drugs, the cost of ART. Research methods: system analysis, data synthesis and generalization of information, webometric analysis, statistical analysis of data on the number of ART cycles for 1999-2018, analysis of ART costs. It is determined that the indicator of the number of ART cycles per 1 million population increased 29.9 times for 1999–2018, which is due to the increase in the number of ART centers conducted ART cycles in relation to the decrease in the population of Ukraine. It was found that 85% of ART centers are concentrated in only 4 cities (Kyiv, Lviv, Odessa, Kharkiv), which reduces the accessibility of the population to ART cycles, especially in the conditions of quarantine and pandemic COVID-19. It was found that in 1999–2018 the number of ART centers increased 7.7 times, but only 10.8% of ART centers have state funding, which indicates the low availability of ART for budget funds. It was found that the structure of ART cycles changed significantly. The average costs for the most common ART cycles IVF and ICSI in Ukraine as of the end of 2019 have been determined. It has been shown that only 26% of ART centers provide information on the cost of ART cycles, and web pages need to be filled with information on the cost of ART cycles to ensure that patients are properly informed. It is shown that in Ukraine as of 2020 the costs of ART cycles are 24 425–30 516 UAH (917,25–1 010,57 Euro) depending on the type of cycle from the perspective of the payer. It is estimated that the availability of ART is 1.5–9.98 depending on the type of ART cycle, the cost of ART cycles is 6–10 times higher than the average family income, when in European countries the availability of ART is much lower 1,5–4.2, which showed higher availability of ART in European countries from payer prospect.
- Open Access
- 9 July 2020
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 3,p. 69-79
Retrospective analysis of prescriptions for the treatment of cardiovascular diseases in the program «Affordable medicines» on the example of a pharmacy
Improving access and affordability for patients of essential drugs in the treatment of cardiovascular diseases is a priority because mortality and a morbidity rates are high in Ukraine. In April 2017, the government launched the reimbursement program «Affordable medicines», which included drugs to treat cardiovascular disease. The aim of the study was a retrospective analysis of released prescriptions on the example of the pharmacy № 1 in Vynohradiv, Transcarpathian region, which serves patients from the city and Vynohradiv district, which allowed us to analyze and compare the structure of the appointments of primary care physicians and to identify the main INN, stocks of which should be a priority in pharmacies for the treatment of cardiovascular diseases. The objects of study were the records of the pharmacies about drugs released in the program for 24 months, the Orders of the Ministry of Health of Ukraine, the CMU Decisions, the Drug Registry for cardiovascular diseases, the cost for reimbursement in the program «Affordable Medicines» as well. Frequency analysis methods, ATC/DDD methodology, as well as methods of comparative, logical and content analysis were used. Data for the selected period were analyzed using frequency analysis methods and ATC/DDD method, and it was found that enalapril, spironolactone and clopidogrel were in the lead. It was found that the majority of patients in 2017 chose free drugs (more than 80%), and in 2018–2019 this rate was only 60%. According to prescriptions, about 92% are patients from Vynohradiv district, which confirms the improvement of access to drugs in the program «Affordable Medicines» for the rural population. The results were verified by comparing the released e-prescriptions for cardiovascular diseases in the city and district and found that the structure of prescriptions for cardiovascular diseases on e-prescriptions from April 2019 to April 2020 remains stable and the main share is 4 INN: clopidogrel, enalapril, amlodipine and bisoprolol. It is determined that in order for the «Affordable Medicines» program, the provision and convenience of patients, the pharmacies need to have an expanded list of trade names and a sufficient supply of enalapril, spironolactone, clopidogrel and bisoprolol.
- 9 July 2020
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 3,p. 69-79
Open AccessRetrospective analysis of prescriptions for the treatment of cardiovascular diseases in the program «Affordable medicines» on the example of a pharmacy
Improving access and affordability for patients of essential drugs in the treatment of cardiovascular diseases is a priority because mortality and a morbidity rates are high in Ukraine. In April 2017, the government launched the reimbursement program «Affordable medicines», which included drugs to treat cardiovascular disease. The aim of the study was a retrospective analysis of released prescriptions on the example of the pharmacy № 1 in Vynohradiv, Transcarpathian region, which serves patients from the city and Vynohradiv district, which allowed us to analyze and compare the structure of the appointments of primary care physicians and to identify the main INN, stocks of which should be a priority in pharmacies for the treatment of cardiovascular diseases. The objects of study were the records of the pharmacies about drugs released in the program for 24 months, the Orders of the Ministry of Health of Ukraine, the CMU Decisions, the Drug Registry for cardiovascular diseases, the cost for reimbursement in the program «Affordable Medicines» as well. Frequency analysis methods, ATC/DDD methodology, as well as methods of comparative, logical and content analysis were used. Data for the selected period were analyzed using frequency analysis methods and ATC/DDD method, and it was found that enalapril, spironolactone and clopidogrel were in the lead. It was found that the majority of patients in 2017 chose free drugs (more than 80%), and in 2018–2019 this rate was only 60%. According to prescriptions, about 92% are patients from Vynohradiv district, which confirms the improvement of access to drugs in the program «Affordable Medicines» for the rural population. The results were verified by comparing the released e-prescriptions for cardiovascular diseases in the city and district and found that the structure of prescriptions for cardiovascular diseases on e-prescriptions from April 2019 to April 2020 remains stable and the main share is 4 INN: clopidogrel, enalapril, amlodipine and bisoprolol. It is determined that in order for the «Affordable Medicines» program, the provision and convenience of patients, the pharmacies need to have an expanded list of trade names and a sufficient supply of enalapril, spironolactone, clopidogrel and bisoprolol.
- 1 May 2020
- Published by Elsevier in Value in Health
- Vol. 23, S243
PMU54 ANALYSIS OF E-PRESCRIPTION SYSTEM AND AWARENESS OF PHARMACISTS ON REIMBURSEMENT PROGRAM IN UKRAINE
- 1 May 2020
- Published by Elsevier in Value in Health
- Vol. 23, S243
PMU54 ANALYSIS OF E-PRESCRIPTION SYSTEM AND AWARENESS OF PHARMACISTS ON REIMBURSEMENT PROGRAM IN UKRAINE
- Open Access
- 9 September 2019
- Published by Ternopil State Medical University in Фармацевтичний часопис
- No. 3,p. 83-91
АНАЛІЗ РЕАЛЬНИХ ДАНИХ ПРИЗНАЧЕНЬ ЛІКАРСЬКИХ ЗАСОБІВ У ПРОТОКОЛАХ СТИМУЛЯЦІЇ ПРИ ДОПОМІЖНИХ РЕПРОДУКТИВНИХ ТЕХНОЛОГІЯХ В УКРАЇНІ
Значна поширеність показників безпліддя серед жінок та чоловіків в Україні за останні 5 років зростання в 3 рази, вимагає застосування допоміжних репродуктивних технологій (ДРТ). Мета роботи – вивчити реальні дані призначень лікарських засобів і витрат на них у протоколах стимуляції при ДРТ на основі ретроспективного аналізу медичних карт пацієнток у державному та приватному медичних центрах з ДРТ. Матеріали і методи. Аналіз частоти призначень, ранжування за витратами та ступенем важливості препаратів провели з допомогою АВС, VEN - аналізу та інтегрованого частотного / АВС, VEN- аналізу. Результати і обговорення. Частотний аналіз показав, що найбільш призначуваними препаратами за частотою у протоколах стимуляції жінок, які включені у Державну Програму лікування, були: хоріонічний гонадотропін, кислота ацетилсаліцилова, ганірелікс; а у приватному медичному центрі для жінок з довгим чи коротким протоколом лікування - полівітаміни з мікроелементами, прогестерон, кислота ацетилсаліцилова. Таким чином, структура призначень ЛЗ у протоколах стимуляції овуляції жінкам у приватному центрі показує, що найвищу частоту призначень мають вітамінно-мінеральні комплекси, які не включені у Протоколи лікування. Нами встановлено, що вартість курсу лікування на початку 2019 року (оптові ціни ЛЗ) у приватній структурі для жінки коротким протоколом стимуляції овуляції у середньому становить 15237,48 грн, при використанні довгого протоколу становлять 22793,86 грн., тобто є на 33,2% вищі витрати для пацієнтки. Висновки. Встановлено, що при використанні довгого протоколу стимуляції 77% витрат припадає на ЛЗ, які є життєво необхідними при ДРТ, 16 % - на основні (essential) ЛЗ та 7% - на другорядні ЛЗ. Для короткого протоколу стимуляції овуляції 73% витрат припадає на ЛЗ, які належать до категорії “V”, 10% - для категорії “Е” та майже 17% - на другорядні ЛЗ, тому виявлено напрями оптимізації призначень у цих схемах ДРТ. Виявлено, що у довгих та коротких протоколах стимуляції овуляції у приватному центрі використовуються ЛЗ, які належать до другорядних, що вимагає оптимізації призначень для раціональності витрат. Перспективним є фармакоекономічний аналіз схем стимуляції за показниками «витрати-ефективність» для визначення економічно вигідних препаратів на курс лікування.
- 9 September 2019
- Published by Ternopil State Medical University in Фармацевтичний часопис
- No. 3,p. 83-91
Open AccessАНАЛІЗ РЕАЛЬНИХ ДАНИХ ПРИЗНАЧЕНЬ ЛІКАРСЬКИХ ЗАСОБІВ У ПРОТОКОЛАХ СТИМУЛЯЦІЇ ПРИ ДОПОМІЖНИХ РЕПРОДУКТИВНИХ ТЕХНОЛОГІЯХ В УКРАЇНІ
Значна поширеність показників безпліддя серед жінок та чоловіків в Україні за останні 5 років зростання в 3 рази, вимагає застосування допоміжних репродуктивних технологій (ДРТ). Мета роботи – вивчити реальні дані призначень лікарських засобів і витрат на них у протоколах стимуляції при ДРТ на основі ретроспективного аналізу медичних карт пацієнток у державному та приватному медичних центрах з ДРТ. Матеріали і методи. Аналіз частоти призначень, ранжування за витратами та ступенем важливості препаратів провели з допомогою АВС, VEN - аналізу та інтегрованого частотного / АВС, VEN- аналізу. Результати і обговорення. Частотний аналіз показав, що найбільш призначуваними препаратами за частотою у протоколах стимуляції жінок, які включені у Державну Програму лікування, були: хоріонічний гонадотропін, кислота ацетилсаліцилова, ганірелікс; а у приватному медичному центрі для жінок з довгим чи коротким протоколом лікування - полівітаміни з мікроелементами, прогестерон, кислота ацетилсаліцилова. Таким чином, структура призначень ЛЗ у протоколах стимуляції овуляції жінкам у приватному центрі показує, що найвищу частоту призначень мають вітамінно-мінеральні комплекси, які не включені у Протоколи лікування. Нами встановлено, що вартість курсу лікування на початку 2019 року (оптові ціни ЛЗ) у приватній структурі для жінки коротким протоколом стимуляції овуляції у середньому становить 15237,48 грн, при використанні довгого протоколу становлять 22793,86 грн., тобто є на 33,2% вищі витрати для пацієнтки. Висновки. Встановлено, що при використанні довгого протоколу стимуляції 77% витрат припадає на ЛЗ, які є життєво необхідними при ДРТ, 16 % - на основні (essential) ЛЗ та 7% - на другорядні ЛЗ. Для короткого протоколу стимуляції овуляції 73% витрат припадає на ЛЗ, які належать до категорії “V”, 10% - для категорії “Е” та майже 17% - на другорядні ЛЗ, тому виявлено напрями оптимізації призначень у цих схемах ДРТ. Виявлено, що у довгих та коротких протоколах стимуляції овуляції у приватному центрі використовуються ЛЗ, які належать до другорядних, що вимагає оптимізації призначень для раціональності витрат. Перспективним є фармакоекономічний аналіз схем стимуляції за показниками «витрати-ефективність» для визначення економічно вигідних препаратів на курс лікування.
- Open Access
- 14 August 2018
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 1-2,p. 22-31
Research of the system of information providing for safe pharmacotherapy pregnancy in the world
Improvement of information provision for safe and rational use of medicines at pregnancy is a priority task for all system of healthcare in the world. The purpose of this study was to analyze and carry out a systematic analysis of information sources, databases, registries operating on the international, state, professional levels on the safe use of medicines, including duration pregnancy in the countries of the world. Summarized recommendations, directives of the World Health Organization about safety of pharmacotherapy, especially during pregnancy, and the need for improvement information provision for the appointment of drugs during pregnancy, since 50% and more pregnant women use more than 4 drugs. Systematized the main sources of information, a database of safe use of medicines during prеgnancy in Europe and the United States on professional levels, as well as specially for patients. The directions of the real word data collection were shown and made the establishment of registries of pregnant women taking medications that allow monitoring of adverse reactions during pregnancy. The modern trends on improving information provision by Food and Drug Administration (FDA) also for instructions and labeling of drugs depending on the risk category of pregnancy were presented. The use of modern information sources, databases, patient registries is relevant to provision of rational use of medicines, especially for pregnant women in Ukraine.
- 14 August 2018
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 1-2,p. 22-31
Open AccessResearch of the system of information providing for safe pharmacotherapy pregnancy in the world
Improvement of information provision for safe and rational use of medicines at pregnancy is a priority task for all system of healthcare in the world. The purpose of this study was to analyze and carry out a systematic analysis of information sources, databases, registries operating on the international, state, professional levels on the safe use of medicines, including duration pregnancy in the countries of the world. Summarized recommendations, directives of the World Health Organization about safety of pharmacotherapy, especially during pregnancy, and the need for improvement information provision for the appointment of drugs during pregnancy, since 50% and more pregnant women use more than 4 drugs. Systematized the main sources of information, a database of safe use of medicines during prеgnancy in Europe and the United States on professional levels, as well as specially for patients. The directions of the real word data collection were shown and made the establishment of registries of pregnant women taking medications that allow monitoring of adverse reactions during pregnancy. The modern trends on improving information provision by Food and Drug Administration (FDA) also for instructions and labeling of drugs depending on the risk category of pregnancy were presented. The use of modern information sources, databases, patient registries is relevant to provision of rational use of medicines, especially for pregnant women in Ukraine.
- 1 May 2018
- Published by Elsevier in Value in Health
- Vol. 21, S125
ANALYSIS OF COST FOR ART CYCLES IN UKRAINE
- 1 May 2018
- Published by Elsevier in Value in Health
- Vol. 21, S125
ANALYSIS OF COST FOR ART CYCLES IN UKRAINE
- 1 October 2017
- Published by Elsevier in Value in Health
- Vol. 20 (9) , A521
Analysis of Real Data for Treatment of Preterm Birth in Pregnant in Ukraine
- 1 October 2017
- Published by Elsevier in Value in Health
- Vol. 20 (9) , A521
Analysis of Real Data for Treatment of Preterm Birth in Pregnant in Ukraine